JP2009535410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535410A5 JP2009535410A5 JP2009509708A JP2009509708A JP2009535410A5 JP 2009535410 A5 JP2009535410 A5 JP 2009535410A5 JP 2009509708 A JP2009509708 A JP 2009509708A JP 2009509708 A JP2009509708 A JP 2009509708A JP 2009535410 A5 JP2009535410 A5 JP 2009535410A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- ischemia
- pyrroloquinoline quinone
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims description 74
- 239000000203 mixture Substances 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 206010063837 Reperfusion injury Diseases 0.000 claims description 29
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 27
- 208000037906 ischaemic injury Diseases 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 7
- 230000010410 reperfusion Effects 0.000 claims description 7
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 6
- 229960002237 metoprolol Drugs 0.000 claims description 6
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical group CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims description 6
- 229960003081 probenecid Drugs 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical group CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 claims description 4
- 229960004912 cilastatin Drugs 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000001607 nephroprotective effect Effects 0.000 claims description 3
- 239000003223 protective agent Substances 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 208000013875 Heart injury Diseases 0.000 claims description 2
- 206010022680 Intestinal ischaemia Diseases 0.000 claims description 2
- 206010061225 Limb injury Diseases 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 206010061481 Renal injury Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000037806 kidney injury Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims 6
- 230000000977 initiatory effect Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79716906P | 2006-05-02 | 2006-05-02 | |
| PCT/US2007/010721 WO2007130509A2 (en) | 2006-05-02 | 2007-05-02 | Pyrroloquinoline quinones and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535410A JP2009535410A (ja) | 2009-10-01 |
| JP2009535410A5 true JP2009535410A5 (enExample) | 2011-06-30 |
Family
ID=38562815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009509708A Withdrawn JP2009535410A (ja) | 2006-05-02 | 2007-05-02 | ピロロキノリンキノンおよびその使用 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2068879A2 (enExample) |
| JP (1) | JP2009535410A (enExample) |
| WO (1) | WO2007130509A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2067781B1 (en) * | 2006-09-19 | 2013-07-24 | Mitsubishi Gas Chemical Company, Inc. | Pyrroloquinoline quinone for improving insulin resistance |
| US9216185B2 (en) | 2008-07-11 | 2015-12-22 | Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon | Use of cilastatin to reduce nephrotatoxicity of various compounds |
| US10806711B2 (en) * | 2011-08-12 | 2020-10-20 | University Of Cincinnati | Method of treating acute decompensated heart failure with probenecid |
| MX376077B (es) * | 2013-03-13 | 2025-03-07 | Univ Cincinnati | Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2. |
| KR101913326B1 (ko) * | 2016-03-29 | 2018-10-30 | 순천향대학교 산학협력단 | 실라스타틴을 포함하는, 신장 허혈 재관류 손상의 예방 또는 치료용 약학적 조성물 |
| JP6548803B1 (ja) | 2018-04-27 | 2019-07-24 | 国立大学法人 新潟大学 | 腎障害の抑制におけるシラスタチンの利用 |
| CN110870866A (zh) * | 2018-09-03 | 2020-03-10 | 浙江医药股份有限公司新昌制药厂 | 吡咯喹啉醌在制备用于防治急性高原反应和急性高原低氧损伤的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997854A (en) * | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
| JP4777489B2 (ja) * | 1997-03-31 | 2011-09-21 | ザ チルドレンズ メディカル センター コーポレーション | アポトーシス性酵素を不活性化するためのニトロシル化 |
| WO2005107871A2 (en) * | 2004-05-05 | 2005-11-17 | Clf Medical Technology Acceleration Program, Inc. | Pyrroloquinoline quinone drugs for treatment of cardiac injury |
| US20060199241A1 (en) * | 2005-03-02 | 2006-09-07 | Hyoungsik Yim | Electrochemically and optically monitoring cleaving enzyme activity |
-
2007
- 2007-05-02 WO PCT/US2007/010721 patent/WO2007130509A2/en not_active Ceased
- 2007-05-02 JP JP2009509708A patent/JP2009535410A/ja not_active Withdrawn
- 2007-05-02 EP EP07794516A patent/EP2068879A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009535410A5 (enExample) | ||
| JP2008501705A5 (enExample) | ||
| JP2023002662A5 (enExample) | ||
| JP2022058688A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| JP2021100937A5 (enExample) | ||
| CN101431990B (zh) | 包含3-（3-二甲基氨基-1-乙基-2-甲基-丙基）-酚和对乙酰氨基酚的药物结合 | |
| JP2006503850A5 (enExample) | ||
| JP2010523714A5 (enExample) | ||
| JP2004521108A5 (enExample) | ||
| JP2008535867A5 (enExample) | ||
| JP2005537268A5 (enExample) | ||
| JP2011505356A5 (enExample) | ||
| RU2009110452A (ru) | Галеновые составы алискирена | |
| JP2012111764A5 (enExample) | ||
| JP2011528713A5 (enExample) | ||
| JP2008525468A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2009102342A5 (enExample) | ||
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| JP2023166406A5 (enExample) | ||
| JP2014516942A5 (enExample) | ||
| WO2009043834A1 (en) | Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound | |
| WO2009032870A3 (en) | Method to ameliorate oxidative stress and improve working memory via pterostilbene administration | |
| JP2013501802A5 (enExample) |